EMA Withdrawn: Raptiva (efalizumab) — Serono Europe Limited

View source ↗

Summary

Raptiva (efalizumab) has been withdrawn from the market in Europe by Serono Europe Limited for psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Raptiva (efalizumab)

Snippet

Status: Withdrawn. Therapeutic area: Psoriasis. MAH: Serono Europe Limited. Decision date: 25/11/2008